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Clinical InvestigationsToward personalized risk assessment in
patients with chronic heart failure: Detailed
temporal patterns of NT-proBNP, troponin T,
and CRP in the Bio-SHiFT study
Nick van Boven, MD, a,b,1 Linda C. Battes, MD, PhD, b,1 K. Martijn Akkerhuis, MD, PhD, b Dimitris Rizopoulos, PhD, c
Kadir Caliskan, MD, PhD, b Sharda S. Anroedh, MD, b Wisam Yassi, MD, a Olivier C. Manintveld, MD, PhD, b
Jan-Hein Cornel, MD, PhD, a Alina A. Constantinescu, MD, PhD, b Eric Boersma, PhD, b Victor A. Umans, MD, PhD, a
and Isabella Kardys, MD, PhDb Alkmaar, and Rotterdam, the NetherlandsBackground We examined the prognostic information of detailed temporal patterns of N-terminal proBNP (NT-
proBNP), high-sensitive troponin T (HsTNT), and C-reactive protein (CRP) in patients with chronic heart failure.
Methods The first inclusion round (2011-2013, N = 263) from the ongoing Bio-SHiFT study was used. Biomarkers were
measured at baseline and every 3 months. The primary end point (PE) comprised heart failure hospitalization, cardiovascular
mortality, cardiac transplantation, and left ventricular assist device implantation. Associations between temporal biomarker
patterns and the PE were investigated by joint modeling.
Results Mean age was 67 ± 12 years, 72% were men, 95% had systolic dysfunction, and 73% were in New York Heart
Association class I or II. Median follow-up was 2.2 (interquartile range 1.4-2.5) years. We used 2,022 blood samples (median
9 [interquartile range 5-10] per patient), and 70 (27%) patients reached the PE. Temporal patterns of NT-proBNP, HsTNT, and
CRP level were associated with the PE (multivariable-adjusted hazard ratio per doubling of biomarker: NT-proBNP 2.28 (95%
CI 1.82-2.86), HsTNT 2.05 (1.63-2.58), and CRP 1.65 (1.30-2.08). A combined 3-biomarker model demonstrated
independent associations for the temporal patterns of NT-proBNP and CRP level (hazard ratios 2.06 [1.53-2.79] and 1.38
[1.01-1.89], respectively). Instantaneous change in biomarker level was also independently associated with the PE for NT-
proBNP and CRP. Long-term biomarker elevation showed an association for NT-proBNP.
Conclusions Temporal patterns representing evolution of level and rate of change in level of NT-proBNP and CRP, and
long-term elevation of NT-proBNP were independently associated with adverse prognosis in patients with chronic heart failure.
Individual patterns of change and combining multiple biomarkers could carry value for prognostication and for therapy
guidance. (Am Heart J 2018;196:36-48.)The diagnosis of progression of chronic heart failure
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https://doi.org/10.1016/j.ahj.2017.10.008symptoms of progression have become manifest. Blood
biomarkers are capable of monitoring subtle (patho)-
physiological processes that reflect and possibly predict
adverse changes before they become clinically appar-
ent.1,2 B-type natriuretic peptides (BNP) and N-terminal
proBNP (NT-proBNP), cardiac troponin T and I, and
C-reactive protein (CRP) have been unequivocally related
to adverse clinical outcomes in patients with heart failure
(HF) in several large studies.2-12
Most of these studies have examined single, baseline
measurements of these blood biomarkers. However,
because patients with CHF display large biological
heterogeneity, distinguishing patients at different levels
of risk of adverse events based on single biomarker
measurements only is challenging. Measuring biomarkers
repeatedly could contribute to individualized risk
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marker patterns over time have mostly focused on
natriuretic peptides, generally used only few repeated
biomarker measurements, and have used simplified
representations of temporal biomarker evolution, such
as change between 2 time points.3-6,12-14 Results of
these studies strongly depend on the statistical
approach that was used.1 Subsequent trials on natri-
uretic peptide-guided therapy of HF have provided
inconsistent results.8-10,15,16 Although such trials are
promising for individual risk assessment and personal-
ized treatment, most existing trials have applied
uniform natriuretic peptide cutoff values for all patients
and did not use individualized target levels, nor did they
take into consideration multiple biomarkers. Moreover,
they did not investigate optimal frequency of the
measurements, nor did they adapt this frequency to
the patient's individual situation.
The above illustrates that to properly install person-
alized risk assessment that makes use of blood
biomarkers, first, more detailed information is needed
on temporal biomarker patterns in individual patients.
Specifically, having measurements available that are
performed closely in time to the moment that the end
point of interest occurs would provide further insight
into the biomarkers' behavior as this end point nearly
approaches. This would enable an adequate investiga-
tion of whether, and to which degree, increasing (or
decreasing) biomarker levels contribute to an indivi-
dual's risk regardless of whether his or her blood levels
exceed classic, absolute cut points at any random point
in time (such as “study baseline”). However, in
practice, biomarker measurements performed shortly
before the end point occurs are difficult to acquire
because they require a high frequency of blood
sampling during prolonged follow-up. Therefore, most
studies on this topic have performed only 2 measure-
ments over time and are thus not able to properly
investigate the biomarker trajectory shortly before the
end point occurs.
In the current study, we have performed frequent (up
to 11), repeated measurements of multiple blood
biomarkers (NT-proBNP, HsTNT, and CRP) in 263
patients with CHF and have investigated the associa-
tions of the thus obtained temporal patterns with
adverse clinical outcome. These 3 biomarkers were
chosen because each of them represents different
aspects of HF pathophysiology (wall stress, myocyte
damage, and inflammation) and because a large body of
evidence exists for the prognostic value of single
measurements of these markers. By performing multi-
ple, longitudinal measurements; assessing multiple
biomarkers simultaneously; and using appropriate,
modern statistical methods, we aimed to provide a
basis for improved, personalized risk assessment in
patients with CHF.Methods
Patients
Bio-SHiFT is a prospective, observational study of stable
outpatients with CHF conducted in Erasmus MC,
Rotterdam, the Netherlands, and Noordwest Ziekenhuis-
groep, Alkmaar, the Netherlands. Patients were recruited
during their regular outpatient visits and were in clinically
stable condition. Detailed inclusion and exclusion criteria
are shown in Figure 1. Patients were eligible if CHF
(including HF with preserved ejection fraction) was
diagnosed ≥3 months ago according to the guidelines of
the European Society of Cardiology.17-19 This study was
approved by the medical ethics committee of the
Erasmus MC, Rotterdam, the Netherlands, and was
conducted in accordance with the Declaration of
Helsinki. Written informed consent was obtained from
all patients. The study is registered in ClinicalTrials.gov,
number NCT01851538. Estimated enrolment is 400
patients. In this article, we have performed an interim
analysis on the 263 patients who were enrolled during
the first inclusion period between October 2011 and June
2013.
Baseline assessment
At baseline, patients were evaluated by trained research
physicians, who collected information on HF-related
symptoms, including New York Heart Association
(NYHA) class,17,18 and performed physical examination,
including blood pressure, heart rate, and body mass
index. Information on etiology of HF, presence of systolic
dysfunction, cardiovascular risk factors, medical history,
and medical treatment was retrieved primarily from
hospital records. History of chronic renal failure was
defined as glomerular filtration rate b60 mL/min/1.73 m2.
Alcohol consumption was defined as drinking ≥1
alcoholic consumption per day. Data were entered into
electronic case report forms. Electrocardiography and
echocardiography were performed. Nonfasting blood
and urine were collected, as described below.
Follow-up visits
Routine outpatient follow-up by the treating physician
continued for all patients during the study. Study
follow-up visits were scheduled every 3 months (a
window of ±1 month was allowed) to a maximum
follow-up duration of 30 months. At each follow-up visit,
a short medical evaluation was performed, and blood and
urine samples were collected. Changes in medication as
well as occurrence of adverse cardiovascular events since
the previous visit were recorded.
Blood sampling and biomarker measurement
Blood samples were processed and stored at a
temperature of −80°C within 2 hours after blood
collection. When applicable, samples were transported
Figure 1
Inclusion and exclusion criteria.
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Netherlands) under controlled conditions (at a tempera-
ture of −80°C) until batch analysis was performed.
Accordingly, results of the biomarker assays were not
available to treating physicians at the time of the
outpatient visits. Thus, the biomarker measurements
performed for this study did not lead to drug adjustments,
and all patients received usual care. This concurs with
Bio-SHiFT being a strictly observational study, as
described above.
For the purpose of the current analysis, 3 biomarkers
(NT-proBNP, HsTNT, and CRP) were measured in 1 batch
in stored serum samples. Plasma NT-proBNP was analyzed
using an electrochemiluminescence immunoassay (Elecsys
2010; Roche Diagnostics, Indianapolis, IN), which mea-
sures concentrations ranging from 5 to 35,000 ng/L.
Cardiac troponin T was also measured using an electro-
chemiluminescence immunoassay (Elecsys 2010 immuno-assay analyzer; Roche Diagnostics, Indianapolis, IN) which
measures concentrations ranging from 3 to 10,000 ng/L.
CRP was measured using an immunoturbidimetric assay
(Roche Hitachi 912 chemistry analyzer; Roche, Basel,
Switzerland). This system measures concentrations rang-
ing from 0.3 to 350 mg/L. All coefficients of variation were
b5%.
Clinical study end points
During follow-up, hospitalizations for HF, myocardial
infarction (MI), percutaneous coronary interventions
(PCIs), coronary artery bypass grafting (CABG), arrhyth-
mias, and cerebrovascular accidents (CVAs), as well as
cardiac transplantation, left ventricular assist device
(LVAD) implantation, and mortality, were recorded in
the electronic case report form by trained research
physicians, and associated hospital records and discharge
letters were collected.
Table I. Baseline characteristics
Total (N = 263)
n (%)/mean (±SD)/median
(25th-75th percentile)
Demographics
Age 67 (±13)
Male gender 189 (72)
Caucasian ethnicity 244 (94)
Clinical characteristics
Body mass index, kg/m2 28 (±5)
Heart rate, beat/min 67 (±12)
Systolic blood pressure, mm Hg 122 (±20)
Diastolic blood pressure, mm Hg 73 (±11)
Biomarker level
NT-proBNP (ng/L) 1161 (439-2305)
HsTNT (ng/L) 18.0 (9.6-33.2)
CRP (mg/L) 2.2 (0.9-4.8)
Features of HF
Duration of HF, y 4.6 (1.7-9.9)
NYHA class I or II 190 (73)
NYHA class III or IV 69 (27)
Left ventricular function
Systolic dysfunction 250 (95)
HFPEF 13 (5)
LVEF⁎ 32 (±10)
Etiology of HF
Ischemic heart disease 117 (44)
Hypertension 34 (13)
Secondary to valvular heart disease 12 (5)
Cardiomyopathy 68 (26)
Dilated 49 (19)
Hypertrophic 12 (5)
Non compaction 4 (1)
Unclassified 3 (1)
Unknown 19 (7)
Other 13 (5)
Medical history
Myocardial infarction 94 (36)
PCI 82 (31)
CABG 43 (16)
Valvular heart disease 136 (53)
Atrial fibrillation 105 (40)
Other arrhythmia 82 (32)
ICD 151 (59)
CRT 78 (30)
Pacemaker 38 (15)
CVA 41 (16)
Chronic renal failure 136 (53)
Diabetes mellitus 81 (31)
Known hypercholesterolemia 93 (35)
Hypertension 120 (46)
Sleep apnea 26 (10)
Intoxications
Alcohol consumption (N1 U/d) 108 (42)
Smoking 185 (71)
Ever 186 (72)
Current 26 (10)
Medication use
ACE-I 173 (67)
ARB 75 (29)
Aldosterone antagonist 178 (68)
Diuretic 237 (90)
β-Blocker 232 (88)
Aspirin 45 (17)
(continued on next page)
Table I (continued)
Total (N = 263)
n (%)/mean (±SD)/median
(25th-75th percentile)
Vitamin K antagonist 200 (77)
Nitrates 44 (17)
Digoxin 59 (23)
Antiarrhythmics 39 (15)
Normally distributed continuous variables are presented as mean (± SD). Nonnormally
distributed continuous variables are expressed as median (25th-75th percentile).
Categorical variables are expressed as count (percentage). Valid percentages may
vary for some counts because of missing values.
HFPEF, Heart failure with preserved ejection fraction; LVEF, left ventricular ejection
fraction; ICD, implantable cardioverter/defibrillator; CRT, cardiac resynchronization
therapy; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker.
⁎Baseline echocardiograms were available in 72% of all patients because of logistic
reasons.
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were reviewed by a clinical event committee blinded to
the biomarker results, and primary and secondary end
points were adjudicated. The primary end point com-
prised the composite of cardiac death, cardiac transplan-
tation, LVAD implantation, and hospitalization for HF,
whichever occurred first in time. Secondary end points
included individual components of the primary end point
and also MI, PCI, CABG, CVA, and all-cause mortality.
Cardiac death was defined as death from MI or other
ischemic heart disease (International Classification of
Diseases, 10th Revision: I20-I25), death from other heart
disease including HF (I30-I45 and I47-I52), sudden cardiac
death (I46), sudden death undefined (R96), or unwit-
nessed or ill-described death (R98, R99). Hospitalization
for acute or worsened HF was primarily based on
exacerbation of HF symptoms requiring hospitalization.
On top of this, a combination of 2 of the following was
required: BNP or NT-proBNP N3× upper limit of normal;
signs of worsening HF, such as pulmonary rales; raised
jugular venous pressure or peripheral edema; increased
dose or intravenous administration of diuretics; or
administration of positive inotropic agents.
Statistical analysis
Distributions of continuous variables, including bio-
marker concentrations, were tested for normality using
the Kolmogorov-Smirnov test. Normally distributed
continuous variables are presented as mean ± SD.
Nonnormally distributed continuous variables are
expressed as median and interquartile range (IQR).
Categorical data are displayed as count and percentage.
In case of skewed distributions, continuous variables
were logarithmically transformed (log base 2) for further
analyses. Associations between patient characteristics
and baseline biomarker levels were evaluated using
univariable linear regression. Associations between
Table II. End points
End point n (%)
Primary
Combined primary end point⁎ 70 (27)
Secondary
Hospitalization for acute or worsening HF 56 (21)
All-cause mortality 32 (12)
Cardiovascular mortality 27 (10)
Heart transplantation 5 (1.9)
Left ventricular assist device implantation 3 (1.1)
Variables are displayed as count (percentage).
⁎ The primary end point comprised HF hospitalization, cardiovascular mortality,
cardiac transplantation, and LVAD implantation.
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marker levels, and the primary end point were evaluated
using Cox proportional-hazards models. These analyses
were first performed univariably. Subsequently, to
evaluate independent associations, all baseline character-
istics that showed statistically significant associations
(with P values b .05) were forced into a multivariable Cox
model.
Associations between temporal biomarker patterns of
each separate biomarker and the primary end point were
assessed using a joint modeling approach, which
combines a linear mixed-effects (longitudinal) submodel
to assess the temporal evolution of the repeatedly
measured marker with a Cox proportional-hazards
submodel to analyze the association of this temporal
evolution with the study end point. In line with the
logarithmic (base 2) transformation of the biomarker
concentrations, the results are presented as hazard ratios
(HRs) per doubling of the biomarker concentration at any
point in time, along with the corresponding 95% CIs.
First, analyses were performed univariably. Subsequently,
potential confounders were entered into the joint
models. These included all variables that were signifi-
cantly associated with the primary end point in the
multivariable “baseline” Cox proportional hazards model
(NYHA class and diabetes mellitus), as well as variables
selected from existing literature (age, gender, renal
function, body mass index). Covariates were missing in
less than 3% of patients. Multiple imputations (5 times) of
these covariates were performed in the multivariable
analyses.
The above-described analysis assesses the predictive
value of repeatedly measured biomarker levels; specifi-
cally, it provides HRs that estimate the risk of the end
point associated with doubling of biomarker level at any
point in time. However, in the context of serial marker
measurements, there could be additional features of the
marker's trajectory that better predict the primary end
point.20 Therefore, we investigated the predictive value
of (1) the “instantaneous slope” of the marker's trajecto-
ry, indicating whether a marker is decreasing, isincreasing, or remains stable, and (2) the area under the
curve of the marker's trajectory, indicating the cumula-
tive effect of all the values the marker has taken in the
past (this area under the curve does not provide
information on increasing or decreasing biomarker
values, which should be derived from the slope).
We chose not to correct for multiple testing because
the selection of the currently investigated 3 biomarkers
was based on previous research and thus hypothesis
driven.2-12
To simultaneously investigate the effect of all 3
biomarkers on the primary end point and thus to assess
their independent predictive value, all individual tempo-
ral biomarker patterns derived from the adjusted joint
models were saved and subsequently entered simulta-
neously as time-varying covariates into an extended Cox
analysis. The same approach was used to investigate the
independent predictive value of the slope and the area
under the curve of the 3 temporal biomarker patterns.
Adjustment for potential baseline confounders was
performed as described above. Additionally, these
extended Cox models were adjusted for temporally
changing total daily doses of equivalents of carvedilol,
enalapril, furosemide, and spironolactone, which were
also entered into the models as time-varying covariates.
To illustrate how joint modeling can be applied to
estimate prognosis of an individual patient based on his or
her repeatedly assessed biomarker values, we plotted the
temporal patterns of the biomarkers in several individual
patients (ie, example patients drawn from our dataset)
together with their corresponding dynamic, individual
probabilities of survival as estimated by the joint model
(which we developed on the total study population as
described above). As such, we graphically demonstrated
individual survival probabilities, which are updated each
time that an additional measurement is performed in the
patient as he or she visits the outpatient clinic.
Finally, to investigate the discriminative ability of
models containing serial measurements and models
containing baseline measurements only, we calculated
C-indices based on extended Cox models containing
temporal biomarker patterns derived from the adjusted
joint models, as well as C-indices based on Cox models
containing baseline biomarker values only.
All analyses were performed with R Statistical Software
using package JM.20 All statistical analyses were 2-sided,
and P values b .05 were considered statistically
significant.
Power calculation
The current investigation comprised 263 patients, of
whom 70 reached the primary end point. For baseline
measurements, these numbers are sufficient to detect
odds ratios around 2 for the upper quintile of a biomarker
associated with the end point (α error .05, power of 80%)
when comparing cases with noncases. For repeated
Table III. Associations between baseline characteristics and the primary end point
Variable Crude HR (CI) P Adjusted HR (CI)‡ P
NT-proBNP (pmol/L)⁎ 1.02 (1.02-1.03) b.001 1.02 (1.01-1.02) b.001
HsTNT (pg/mL)⁎ 1.12 (1.08-1.16) b.001 1.08 (1.02-1.16) .020
CRP (mg/L)⁎ 1.26 (1.06-1.50) .016 1.18 (0.96-1.45) .12
Age† 1.02 (1.01-1.05) .035 1.00 (0.98-1.02) .86
Male gender 1.27 (0.80-2.19) .40
Systolic blood pressure† 0.99 (0.98-0.99) .040 0.99 (0.98-1.01) .26
Diastolic blood pressure† 0.98 (0.96-1.00) .055
Heart rate† 1.01 (0.99-1.03) .24
Body mass index (kg/m2)† 1.00 (0.96-1.05) .88
NYHA class† 2.10 (1.56-2.54) b.001 1.61 (1.14-2.26) .006
Chronic renal failure 2.11 (1.28-3.50) .004 1.25 (0.72-2.18) .42
Diabetes mellitus 2.06 (1.29-3.29) .003 1.91 (1.17-3.11) .010
Hypercholesterolemia 1.37 (0.85-2.20) .20
Hypertension 1.31 (0.82-2.10) .26
Ever smoker 1.48 (0.84-2.62) .18
History of CAD 1.56 (0.96-2.53) .074
History of CVA 1.40 (0.78-2.51) .26
ICD 1.20 (0.74-1.95) .47
CRT 0.80 (0.47-1.36) .42
⁎HR per 10-unit increase.
†HR per unit increase.
‡All characteristics univariably associated with the primary end point (P b .05) were entered into the multivariable Cox regression model.
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samples per patient was available. We calculated power
for repeated measurements by assuming a linear associ-
ation and a continuous autoregressive correlation matrix.
We used NT-proBNP to derive the measurement error
standard deviation (σ, equal to 463) and the input
parameter for the autoregressive correlation matrix (ρ,
equal to 0.49). Based on these input parameters and using
1,000 simulations, we calculated that a difference in
change of NT-proBNP level over time of 51 ng/L per
month can be demonstrated between cases and noncases
(α error .05, power of 80%). This difference is small in
clinical terms, demonstrating that the study has high
statistical power.
Results
Baseline findings
From October 2011 to August 2015, 263 patients were
included. Baseline characteristics are shown in Table I.
Mean age of the study population was 67 years (SD ±12).
The majority were men (72%) in NYHA class I or II (73%).
Median duration of HF was 4.6 years (IQR 1.7-9.9).
Median baseline NT-proBNP was 1161 ng/L (IQR
439-2305), HsTNT was 18.0 ng/L (IQR 9.6-33.2), and
CRP was 2.2 mg/L (IQR 0.9-4.8). Positive associations
were found between baseline NT-proBNP level and age
(P = .01), heart rate (P = .01), NYHA class (P b .001), and
renal failure (P b .001). Inverse associations were found
between NT-proBNP and diastolic blood pressure (P b
.001) and BMI (P b .001). Baseline HsTNT level waspositively associated with age (P b .001), NYHA class (P b
.001), and renal failure (P b .001). Baseline CRP level
showed positive associations with heart rate (P = .01) and
renal failure (P = .045), and inverse associations with
systolic (P = .046) and diastolic blood pressure (P b .001).
Clinical end points
During a median follow-up of 2.2 (IQR 1.4-2.5) years, 27
(10%) patients died from a cardiovascular cause, 56 (21%)
patients were rehospitalized for worsened HF, 5 (1.9%)
patients underwent heart transplantation, and 3 (1.1%)
patients received LVAD implantation (Table II). Because
21 patients were rehospitalized for worsened HF before
dying from cardiovascular causes eventually during
further follow-up, 70 patients (27%) reached the com-
posite primary end point. Overall all-cause mortality was
32 (12%).
Associations between baseline characteristics and the
primary end point are shown in Table III. After
multivariable adjustment, baseline NT-proBNP (HR 1.02,
CI 1.01-1.02), baseline HsTNT (HR 1.08, CI 1.02-1.16),
NYHA class (HR 1.61, CI 1.14-2.26), and diabetes mellitus
type 2 (DM) (HR 1.91, CI 1.17-3.11) were independently
associated with the primary end point (Table III).
Temporal biomarker patterns and the primary end
point
During follow-up, we collected 2,193 blood samples, of
which 2,022 were drawn before the occurrence of the
primary end point (median of 9 [IQR 5-10] samples per
Table IV. Association between temporal patterns of logarithmically transformed NT-proBNP, HsTNT, and CRP and the primary end point
NT-proBNP HsTNT CRP
HR⁎ (95% CI) P value HR⁎ (95% CI) P value HR⁎ (95% CI) P value
Temporal pattern of biomarker level
Adjusted for age and gender 2.20 (1.83-2.65) b.001 2.21 (1.79-2.72) b.001 1.80 (1.43-2.26) b.001
Multivariable adjusted† 2.28 (1.82-2.86) b.001 2.05 (1.63-2.58) b.001 1.65 (1.30-2.08) b.001
Instantaneous slope of temporal pattern
Adjusted for age and gender 2.16 (1.79-2.62) b.001 2.14 (1.71-2.66) b.001 1.85 (1.43-2.41) b.001
Multivariable adjusted† 2.15 (1.71-2.68) b.001 2.02 (1.58-2.58) b.001 1.69 (1.32-2.18) b.001
Area under the curve of temporal pattern
Adjusted for age and gender 1.68 (1.45-1.96) b.001 1.74 (1.46-2.07) b.001 1.32 (1.13-1.55) b.001
Multivariable adjusted† 1.54 (1.30-1.83) b.001 1.55 (1.29-1.86) b.001 1.28 (1.09-1.51) .003
3 Biomarkers combined
Level, multivariable adjusted† 2.06 (1.53-2.79) b.001 1.41 (0.93-2.13) .104 1.38 (1.01-1.89) .047
Level, medication adjusted‡ 2.08 (1.54-2.80) b.001 1.46 (0.95-2.23) .083 1.38 (1.01-1.90) .044
Slope, multivariable adjusted† 2.04 (1.51-2.78) b.001 1.47 (0.94-2.16) .093 1.41 (1.02-1.94) .036
Slope, medication adjusted‡ 2.06 (1.51-2.80) b.001 1.44 (0.94-2.21) .089 1.42 (1.02-1.99) .040
Area, multivariable adjusted† 1.99 (1.49-2.66) b.001 1.42 (0.94-2.13) .092 1.32 (0.96-1.80) .084
Area, medication adjusted‡ 2.01 (1.49-2.73) b.001 1.42 (0.94-2.15) .098 1.26 (0.91-1.75) .16
⁎Hazard ratios are given per doubling of level, slope, or area under the curve at any point in time.
†Adjusted for age, gender, BMI, renal function, NYHA class, and diabetes mellitus type 2.
‡Adjusted for age; gender; and temporally changing total daily doses of equivalents of carvedilol, enalapril, furosemide, and spironolactone.
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marker patterns and the primary end point are shown in
Table IV.
The temporal NT-proBNP pattern derived from the
repeated measurements was a significant predictor of the
primary end point after adjustment for age, gender, BMI,
renal function, NYHA class, and DM (HR per doubling of
NT-proBNP: 2.28, CI 1.82-2.86, P b .001). Figure 2, A
displays the curves depicting the temporal NT-proBNP
pattern of patients who reached the primary end point
versus those who did not.
Figure 2, B depicts temporal HsTNT patterns of patients
who reached the primary end point and those who did
not. We found an association between the temporal
HsTNT pattern and the primary end point, which
remained present after multivariable adjustment (HR
per doubling of biomarker: 2.05, CI 1.63-2.58, P b .001).
As shown in Figure 2, C, the temporal CRP pattern was
also a significant predictor of the primary end point (HR
per doubling of CRP after multivariable adjustment: 1.65,
CI 1.30-2.08, P b .001).
NT-proBNP, HsTNT, and CRP patterns and the
primary end point using a combined 3-biomarker
model. When we combined temporal patterns of all 3
biomarkers in 1 model, we found independent associa-
tions of NT-proBNP (HR per doubling of NT-proBNP level
at any given time point: 2.06, CI 1.53-2.79, P b .001) and
CRP (HR per doubling of CRP level: 1.38, CI 1.01-1.89,
P = .047) with the primary end point. These associations
were also independent of temporally changing total daily
doses of equivalents of carvedilol, enalapril, furosemide,and spironolactone (Table IV). However, HsTNT was no
longer associated with the primary end point in this
model (HR per doubling of HsTNT: 1.41, CI 0.93-2.13, P =
.10), illustrating that its predictive value was not
independent of NT-proBNP and CRP.
Slopes and areas under the curve of temporal
patterns. Table IV displays HRs for the doubling of the
instantaneous slopes and areas under the curve of the
temporal biomarker patterns. The instantaneous slopes of
the temporal patterns as well as the areas under the curve
of NT-proBNP, HsTNT, and CRP were all associated with
the primary end point after multivariable adjustment,
including adjustment for temporally changing total daily
doses of equivalents of carvedilol, enalapril, furosemide,
and spironolactone.
When we entered the instantaneous slopes of the
temporal biomarker patterns of the 3 biomarkers into 1
model, they remained independent predictors for
NT-proBNP and CRP, but not for HsTNT. Simultaneously
entering the areas under the curve of the 3 temporal
biomarker patterns into 1 model showed that only
NT-proBNP was independently associated with the
primary end point.
Personalized prediction: individual, dynamic risk
estimation
Figure 3 shows the temporal patterns of the biomarkers
in several individual patients from our data set together
with their corresponding individual probabilities of
survival as estimated by the joint model. The figure
shows that each time an additional measurement is
Figure 2
Temporal patterns. The temporal patterns, displayed as time until
event, of (A) NT-proBNP, (B) HsTNT, and (C) CRP of patients who
reached the primary end point versus those who did not.
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survival is updated. Specifically, rising marker levels and
worsening prognosis can be seen in the example patients
who ultimately reached the composite end point versus
stable or decreasing marker levels and more favorable
prognosis in the example patients who stayed event-free.
These individual estimates of prognosis can be obtainedby clinicians in an easy, user-friendly manner. Joint
models, like those we have constructed, can be uploaded
into an app (http://shiny.rstudio.com/) that creates an
interface into which a clinician can add the characteris-
tics, and consecutive biomarker measurements, of an
individual patient. Subsequently, the app returns the
curve depicting individual prognosis (Supplemental
Figure 1).
Model performance. Discriminative ability of models
containing the temporal patterns of the biomarker levels
and baseline measurements only is shown in Table V. For
all 3 biomarkers, models containing temporal biomarker
patterns showed higher C-indices than those containing
baseline measurements only. The highest C-index result-
ed from the multivariable model containing all 3 temporal
biomarker patterns as well as age, gender, BMI, renal
function, NYHA class, and DM (C-index 0.84).
Temporal patterns of NT-proBNP, HsTNT, and CRP in
relation to hospitalization for acute or worsening HF
(secondary end point)
All 3 biomarker patterns were strong individual
predictors of HF hospitalizations (age- and gender-
adjusted HRs per doubling of biomarker: NT-proBNP
2.17, CI 1.57-2.66, P b .001; HsTNT 2.18, CI 1.72-2.76, P b
.001; and CRP 1.99, CI 1.53-2.59, P b .001). These
associations remained statistically significant after multi-
variable adjustment (HRs per doubling of biomarker:
NT-proBNP 2.31, CI 1.77-3.01, P b .001; HsTNT 1.95, CI
1.49-2.55, P b .001; and CRP 1.80, CI 1.37-2.35, P b .001).
After creating a time-dependent Cox model using all 3
temporal biomarkers patterns, derived from the individ-
ual joint models, we found that each of the 3 biomarkers
remained independent predictors of HF hospitalizations
(HR per doubling of biomarker: NT-proBNP 1.51, CI
1.26-1.80, P b .001; HsTNT 1.57, CI 1.24-2.00, P = .001;
and CRP 1.41, CI 1.15-1.74, P b .001). These associations
persisted after adjusting for temporally changing total
daily doses of equivalents of carvedilol, enalapril,
furosemide, and spironolactone (HR per doubling of
biomarker: NT-proBNP 1.49, CI 1.23-1.80, P b .001;
HsTNT 1.50, CI 1.18-1.91, P = .001; and CRP 1.39, CI
1.11-1.74, P = .004).
Discussion
We performed a prospective, observational study that
comprised CHF patients with mostly systolic dysfunction
and predominantly favorable NYHA class (I-II). Here, in
the first inclusion round, we demonstrate that the
dynamic, temporal patterns of serially measured
NT-proBNP and CRP levels are strong and independent
predictors of adverse clinical events. Moreover, instanta-
neous slope of these biomarkers' temporal trajectories, as
well as the area under the curve of their temporal
trajectories, is associated with adverse events. The
Figure 3
Dynamic profiling of an individual patient's risk using patient-specific temporal trajectories. The solid red lines depict patients who experienced the
study end point, and the solid blue lines depict patients who did not. The x-axis depicts follow-up time starting from baseline. Biomarker levels (on
the log scale) are displayed on the left y-axis and survival probability (%) on the right y-axis. Patient-specific temporal biomarker trajectories are
displayed left of the vertical dotted black line. To the right of this line, the corresponding conditional survival probability curve is displayed with 95%
CIs (gray area). To show how this conditional survival probability curve is dynamically updated every time an extra measurement is recorded, we
provide the curves for 3 time points at which risk was updated.
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adverse events but lose their predictive capability when
combined with temporal NT-proBNP and CRP patterns.We also demonstrate, based on these dynamic models,
how individual, temporal biomarker trajectories can be
used for calculating patient-specific risk estimates, which
Table V. Discriminative ability of models containing the temporal
patterns of NT-proBNP, HsTNT, and CRP level, as well as models
containing baseline measurements only
Baseline measurements Temporal patterns
C-index; multivariable
model⁎
C-index; multivariable
model⁎
NT-proBNP 0.78 0.83
HsTNT 0.73 0.75
CRP 0.67 0.69
Combined
model†
0.79 0.84
⁎ The multivariable models were corrected for age, gender, BMI, renal function, NYHA
class, and diabetes mellitus type 2.
†NT-proBNP, HsTNT, and CRP are all included in the combined model.
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measurement performed.
Studies on the prognostic value of repeated natriuretic
peptide measurements have mostly been performed in
trial participants,6,13 and studies on the prognostic value
of repeated biomarker measurements other than natri-
uretic peptides are scarce.3,4,12 Altogether, these existing
studies describing temporal changes in biomarkers in
relation to patient prognosis have 3 major limitations.
Firstly, changes are often presented as a difference
between just 2 measurements that are separated in
time. Such an approach fails to fully capture the true
biomarker pattern of the dynamic disease. Moreover, it
fails to expose changes in biomarker level prior to
clinically relevant end points because, on average, a long
time period lies between the last (ie, second) biomarker
measurement and the incident end point. To properly
investigate whether an increase in biomarker level is
present at the time an end point is approaching and
whether this increase truly contributes to an individual's
risk, the time period between the last measurement and
the end point should be kept as brief as possible. This
implies that a high frequency of blood sampling during
prolonged follow-up is needed. Secondly, biomarkers are
often studied in isolation, thus actually ignoring the
different underlying etiologies that converge to adverse
cardiac remodeling and HF progression. The third
limitation of existing studies is related to the applied
methods of data analysis. Often, absolute or relative
differences between 2 measurements are calculated, or
categorical changes across a threshold value are assessed.
These various approaches to temporal change all render
different estimates for associations between changes in
biomarker level and outcome,1 which are an illustration
of their shortcomings. At best, Cox models with so-called
time-dependent covariates are used to analyze the
effects of temporal biomarker patterns. Although time-
dependent Cox models assume that biomarker levels do
not change between measurements, it is known that
biomarker patterns are dynamic and continuously changeover time, parallel to the condition of the patient. All
these limitations are overcome in Bio-SHiFT: we have
performed a large number of frequent, repeated measure-
ments (up to 11 trimonthly samples per patient); we have
studied multiple biomarkers; and we have applied modern
statistical methods (“joint modeling”), which, as stated
above, take into account the continuous, dynamic changes
in biomarker patterns and thus result in less bias.21
Several randomized trials have been performed to
investigate whether using serial natriuretic peptide
measurements to titrate medical therapy can improve
clinical outcome of HF patients. However, because the
results of these trials were not fully consistent, natriuretic
peptide–guided therapy remains controversial.8-10,15 It
should be noted that most of these trials were based on
protocols that used uniform natriuretic peptide targets in
the intervention groups.22-26 Existing trials that used
individualized treatment targets are in the minority and
often based their targets on natriuretic peptide levels that
were measured briefly after the index episode of
decompensation when titration of therapy was still
ongoing.27-29 Conversely, our study describes in detail
the temporal biomarker patterns in stable CHF patients
and reveals significant associations between temporal
patterns of biomarker levels and adverse events. Patients
with CHF who did not experience adverse cardiac events
during prolonged follow-up were shown to have lower
levels of NT-proBNP, HsTNT, and CRP at any moment in
time compared with patients who did experience
adverse cardiac events during follow-up. Additionally,
the instantaneous rate of change in biomarker levels
(represented by the slope of the temporal biomarker
patterns), as well as the cumulative values the marker has
taken in the past (represented by the area under the
temporal biomarker patterns), was associated with
adverse outcome. These findings support the concept
of an individualized biomarker target level instead of a
generally applicable uniform cutoff value for all patients.
On top of this, they suggest that rate of change in
biomarker level and the duration of biomarker level
elevation merit attention to provide appropriate individ-
ual treatment targets as well as correct estimates of
prognosis. Our study also demonstrates that temporal
patterns of CRP predict adverse clinical outcome
independently of NT-proBNP.
Future trials on biomarker-guided therapy may benefit
from incorporating these findings. Firstly, future trials
should use personalized biomarker cutoff values, that is,
interpret a patient's biomarkers level in the context of his
or her previous series of levels. This means that they
should not only take into account the absolute biomarker
level but also incorporate the instantaneous slope of the
marker's trajectory. Secondly, upcoming trials should use
a combination of multiple biomarkers, representing
different pathophysiological pathways, to guide HF
therapy. Finally, additional research should be performed
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tailoring thereof to individual patients; subsequently,
these f indings should be incorporated into
biomarker-guided trials as well.
Miller et al12 published a study that might be
considered comparable to Bio-SHiFT to a certain extent,
as they evaluated serial measurements of cardiac troponin
T and BNP in 190 ambulant CHF patients. Again, an
important limitation of this study is the use of
time-dependent Cox models. Still, Miller et al found that
cardiac troponin T and BNP were both independent
predictors of cardiac mortality or cardiac transplantation
and that combined elevation of these biomarkers
substantially adds to risk. We could only partly confirm
these results. In Bio-SHiFT, although predictive as a
separate marker, the HsTNT pattern appeared to be no
longer significantly associated with the primary study end
point after adjustment for the NT-proBNP and CRP
patterns (and also after adjustment for NT-proBNP
alone; data not shown). This may (at least in part) be
due to the above-described differences in data analysis.
Some aspects of this study warrant consideration. With
263 patients, sample size is limited, and the majority of
the patient population was in NYHA class I or II and had
systolic dysfunction. Also, a large proportion had
concomitant valvular heart disease. The results and
conclusions should be judged accordingly because such
a study population may not be fully representative of
“real-life” CHF patients in general. Nevertheless, given the
repeated-measures design, N2,000 blood samples were
available, and all 3 investigated biomarkers, each having
different pathophysiological properties, showed the
hypothesized rising temporal pattern. This strengthens
our findings and makes them less likely attributable to
bias or chance. Further to this, the current investigation
was an interim analysis of the patients enrolled in the first
inclusion round. The full Bio-SHiFT cohort was designed
to enroll 400 patients and to have sufficient statistical
power to perform large-scale, hypothesis-free research on
novel, lesser known biomarkers. In such cases, correc-
tion for multiple testing is warranted. The current
investigation, however, examines 3 well-established
biomarkers, which have been extensively implicated in
HF in previous studies and which were chosen based on
pathophysiological considerations, rendering correction
for multiple testing redundant. Furthermore, additional
investigations are needed to estimate the most efficient
frequency of biomarker measurement so that optimal
prognostic information can be gained without superflu-
ous blood sampling. In our study, patients were
monitored every 3 months to construct a data framework
for our joint models. An extension to joint modeling is
currently being developed to define optimal time frames
for individual patients to return for consecutive measure-
ments. In this context, the optimal frequency for
biomarker measurement is expected to vary from patientto patient; it is likely that once a stable biomarker value is
found in a patient, this patient could be reexamined after
a longer time period, whereas if, for example, a
biomarker value is found to have risen and thus prognosis
is worsening, the patients may need to return more
quickly. Moreover, in our study, repeatedly measured
NT-proBNP and CRP were both independently associated
with the primary end point. This implies that a multi-
marker model would benefit monitoring of CHF patients
(although a model combining both of these biomarkers
seemed to have little incremental discriminative value
over serial NT-proBNP assessment only as suggested by
the C-index, the C-index is known to be rather
insensitive to improvements in prediction performance,
and it has been demonstrated previously that testing for
improvement in prediction performance is actually
redundant if a variable has already been shown to be
an independent risk factor30). Future studies should
investigate a broader spectrum of biomarkers to further
improve risk assessment. Finally, although we have
illustrated the application of biomarker-guided, person-
alized risk assessment in practice by means of an
interface that uses joint modeling, we realize that
many challenges remain to be resolved before truly
implementing such a strategy.
In conclusion, detailed temporal patterns of NT-proBNP
and CRP are strong, independent predictors of adverse
clinical events in our study population of patients with
stable CHF. Not only evolution of biomarker level but also
instantaneous rate of change in level of NT-proBNP and
CRP as well as the area under the curve of the trajectory
of NT-proBNP was associated with adverse outcome.
These findings suggest that individual patterns of change
of biomarkers, as well as combinations of multiple
biomarkers, should be taken into consideration for
prognostication in patients with stable CHF. Overall,
our study illustrates that several aspects of biomarker-
guided risk stratification have been incompletely ad-
dressed so far and that there still seems to be room for
improvement with regard to personalized risk assess-
ment. Future steps could potentially include determining
optimum timing of blood sampling, determining opti-
mum combinations of biomarkers, and eventually a
biomarker-guided trial that is based on personalized
temporal patterns of multiple biomarkers.
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ahj.2017.10.008.Disclosure
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